ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2120

Predictive Value of Anti-CCP Positivity On Disease Course and Response to Therapy in Early Rheumatoid Arthritis. Results From the Swedish EIRA Study

Saedis Saevarsdottir1, Marie Holmqvist2, Johan Askling3, Lars Alfredsson4 and Lars Klareskog5, 1Rheumatology Unit, Dept. of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, 2Karolinska Institutet, Stockholm, Sweden, 3Department of Medicine, Rheumatology Unit & Clinical Epidemiology Unit, Karolinska Institute, Stockholm, Sweden, 4Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 5Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: anti-CCP antibodies, methotrexate (MTX), prednisolone, prednisone, Prognostic factors and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects III: Infections/Risk Factors for Incident Rheumatoid Arthritis/Metrology/Classification/Biomarkers/Predictors of Rheumatolid Arthritis Activity & Severity

Session Type: Abstract Submissions (ACR)

Background/Purpose: Does anti-CCP-positivity predict disease course and response to therapy in early rheumatoid arthritis (RA)?

Methods: We retrieved clinical follow-up data for patients entering the EIRA cohort 1996-2009 from the Swedish Rheumatology Quality Register (1996-2010). Overall, 1,640 of the 2,567 registered RA patients were followed from diagnosis. Then, 99 received no DMARD treatment, 41 received only prednisolone, 670 only methotrexate, 476 methotrexate and prednisolone, 224 sulfasalazine, whereas 130 patients received other DMARDs or combinations. The association between anti-CCP-positivity and EULAR good response was evaluated by logistic regression and expressed as univariate p-values and multivariate odds ratios (OR) with 95% confidence intervals (CI), adjusted for gender, age, inclusion year, symptom duration, HAQ score and cigarette smoking habits. 

Results:

The proportion starting DMARD/methotrexate at diagnosis increased during the inclusion period (p<0.0001/<0.0001). In the subgroup receiving no DMARD, anti-CCP-positive patients were, compared to anti-CCP-negative patients, less likely to fulfil the criteria for ‘good response’ after 3 months (15% vs. 48%, p=0.002; adjusted odds ratio=0.24; 95%CI 0.07-0.82). A smaller, but significant difference was observed between anti-CCP-positive and anti-CCP-negative patients receiving methotrexate only (31% vs. 41%, p=0.02; adjusted odds ratio=0.65; 95%CI 0.44-0.94), whereas no difference was observed between anti-CCP-positive and anti-CCP-negative patients receiving both methotrexate and prednisolone (52% vs. 49%, p=0.5; adjusted odds ratio=1.23; 95%CI 0.78-1.92). No significant differences were observed in patients receiving sulfasalazine or in the entire cohort during 2 years follow-up.

Conclusion: Anti-CCP positivity predicts persistent disease activity in early RA patients not receiving DMARD treatment, while its predictive value for response is limited in patients treated with MTX, SSZ and prednisolone, and in the entire group of RA patients reflecting all treatment options over time. Our findings also indicate that the less chance of a favorable clinical disease course in anti-CCP positive patients may be compensated for with treatment, namely that today´s standard care with methotrexate and low dose prednisolone may have its main effects in ACPA-positive patients. This highlights the importance of performing a careful subgrouping of the RA syndrome in all controlled as well as observational studies on drug treatment.


Disclosure:

S. Saevarsdottir,
None;

M. Holmqvist,
None;

J. Askling,
None;

L. Alfredsson,
None;

L. Klareskog,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predictive-value-of-anti-ccp-positivity-on-disease-course-and-response-to-therapy-in-early-rheumatoid-arthritis-results-from-the-swedish-eira-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology